CELZ Stock Analysis: Buy, Sell, or Hold?
CELZ - Creative Medical Technology Holdings, Inc. Common Stock
$1.21
-0.06 (-4.72%)
▼
5d:
-39.5%
30d:
-45.74%
90d:
-39.2%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 14, 2026
Get Alerted When CELZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CELZ shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CELZ shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CELZ is currently trading at $1.21, which is considered oversold relative to its 30-day fair value range of $1.58 to $2.40.
Technical Outlook: Technically, CELZ is showing sideways momentum. Immediate support is located at $0.79, while resistance sits at $4.72. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: CELZ has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $20.00 (+1552.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CELZ is showing sideways momentum. Immediate support is located at $0.79, while resistance sits at $4.72. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: CELZ has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $20.00 (+1552.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.58 -
$2.40
Company Quality Score
43/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
47.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BEARISH: Downward momentum (-4.7%)
- BULLISH: Trading 1552.9% below Wall St target ($20.00)
- CAUTION: 5-day price weakness (-39.5%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.58 -
$2.40
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.79
Resistance Level
$4.72
Current Trend
Sideways
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.80
Wall Street Target
$20.00
(+1552.9%)
Earnings Growth (YoY)
358.9%
Share & Embed Analysis
Last updated: July 02, 2026 10:34 PM ET
Data refreshes hourly during market hours. Next update: 11:34 PM
Data refreshes hourly during market hours. Next update: 11:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CELZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
